Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -37.92% | 340.60% | -47.42% | 244.95% | -450.86% |
| Total Depreciation and Amortization | 0.53% | 17.50% | -75.27% | 83.81% | -37.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | 0.00% |
| Total Other Non-Cash Items | 6,957.14% | -94.26% | -71.89% | -0.46% | 20.11% |
| Change in Net Operating Assets | 117.94% | -5.57% | 2.77% | -190.62% | 229.70% |
| Cash from Operations | 50.71% | 2,520.69% | -105.09% | 3.17% | 168.86% |
| Capital Expenditure | -164.97% | -603.57% | 80.28% | 6.58% | -36.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | 527.35% |
| Cash from Investing | -164.97% | -603.57% | 80.28% | -140.80% | 252.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 25.00% | -233.33% | -- | 100.00% | -114.29% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.00% | -233.33% | 76.30% | -68.80% | -114.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.85% | -15.60% | 55.28% | -3,163.83% | 90.91% |
